Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Nov 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Sean Bohen |
Contact Details
Address: 780 Brannan Street San Francisco, California 94103 United States | |
| Phone | 415 651 3316 |
| Website | olema.com |
Stock Details
| Ticker Symbol | OLMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1750284 |
| CUSIP Number | 68062P106 |
| ISIN Number | US68062P1066 |
| Employer ID | 30-0409740 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | President, Chief Executive Officer, Interim Principal Financial Officer and Director |
| Shawnte M. Mitchell J.D. | Chief Legal Officer and Corporate Secretary |
| Shane William Charles Kovacs M.B.A. | Consultant |
| Dr. David C. Myles Ph.D. | Chief Scientific Officer |
| Courtney O'Konek | Vice President of Corporate Communications |
| Julie Dexter | Senior Vice President and Head of People |
| Dr. Naseem Zojwalla M.D. | Chief Medical Officer |
| Richard Hernandez | Senior Vice President of Clinical Development Operations |
| Dr. Mark Shilkrut M.D., Ph.D. | Senior Vice President of Clinical Development |
| Dr. Kamesh Kuchimanchi Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 1, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2026 | 8-K | Current Report |
| Mar 20, 2026 | SCHEDULE 13G | Filing |
| Mar 16, 2026 | 144 | Filing |
| Mar 16, 2026 | 144 | Filing |